Table 1.
Baseline demographic and clinical characteristics among bDMARD-naïve and bDMARD-experienced patients at index date
| bDMARD-naïve patients | bDMARD-experienced patients | |||
|---|---|---|---|---|
| ETN (n = 146) | Other TNFi (n = 274) | ETN (n = 36) | Other TNFi (n = 161) | |
| Age, mean (SD), years [N] | 55.5 (13.0) [146]* | 58.6 (13.7) [274]* | 54.8 (12.4) [36] | 57.6 (13.1) [161] |
| Female, n (%) [N] | 106 (72.6) [146] | 194 (71.1) [273] | 30 (83.3) [36] | 117 (72.7) [161] |
| White, n (%) [N] | 127 (87.0) [146] | 233 (85.0) [274] | 29 (80.6) [36] | 134 (83.2) [161] |
| Duration of RA, mean (SD), years [N] | 8.8 (8.5) [143] | 8.8 (8.2) [273] | 11.5 (9.1) [36] | 11.8 (9.2) [157] |
| RF positive, n (%) [N] | 69 (72.6) [95] | 152 (76.4) [199] | 19 (82.6) [23] | 62 (66.7) [93] |
| aCCP antibody positive, n (%) [N] | 34 (55.7) [61]* | 93 (72.1) [129]* | 13 (86.7) [15] | 42 (71.2) [59] |
| Comorbidities, n (%) [N]† | ||||
| Cardiovascular disease | 1 (0.7) [146]* | 12 (4.4) [274]* | 1 (2.8) [36] | 8 (5.0) [161] |
| Malignancy | 9 (6.2) [146] | 19 (6.9) [274] | 4 (11.1) [36] | 17 (10.6) [161] |
| Serious infection | 4 (3.3) [121] | 7 (3.1) [229] | 1 (3.1) [32] | 7 (5.1) [138] |
| Diabetes | 5 (3.4) [146] | 11 (4.0) [274] | 3 (8.3) [36] | 13 (8.1) [161] |
| mHAQ, mean (SD) score [N] | 0.2 (0.4) [144] | 0.2 (0.4) [266] | 0.3 (0.4) [36] | 0.3 (0.3) [157] |
| CDAI, mean (SD) score | 3.7 (2.9) [146] | 3.5 (3.0) [274] | 5.0 (3.0) [36] | 4.4 (2.9) [161] |
| CDAI category, n (%) | ||||
| Remission | 68 (46.6) | 147 (53.6) | 11 (30.6) | 59 (36.6) |
| LDA | 78 (53.4) | 127 (46.4) | 25 (69.4) | 102 (63.4) |
| PGA, mean (SD) score | 7.7 (7.9) | 7.0 (9.1) | 10.5 (10.4) | 8.9 (8.8) |
| Current prednisone use, n (%) | 15 (10.3) | 29 (10.6) | 9 (25.0)* | 16 (9.9)* |
| No. prior bDMARDs, n (%) | ||||
| 0 | 146 (100) | 274 (100) | 0 | 0 |
| 1 | 0 | 0 | 33 (91.7)* | 117 (72.7)* |
| > 1 | 0 | 0 | 3 (8.3)* | 44 (27.3)* |
aCCP, anti-cyclic citrullinated peptide; bDMARD, biologic disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; ETN, etanercept; mHAQ, modified Health Assessment Questionnaire; PGA, physician global assessment; RA, rheumatoid arthritis; RF, rheumatoid factor; TNFi, tumor necrosis factor inhibitor
*p < 0.05 for ETN monotherapy versus other TNFi monotherapy
†History of or current disease as assessed at index date, during the evaluation of index and baseline characteristics